Alumis Inc.
NASDAQ: ALMS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martin Babler
- Employees
- 223
- Headquarters
- South San Francisco, United States
- IPO year
- 2024
- Market cap
- $3.1B
- Website
- https://www.alumis.com
Loading ALMS…
Loading profile data…Frequently asked questions about ALMS
What does Alumis Inc. (ALMS) do?
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric T...
Where does ALMS trade?
Alumis Inc. (ALMS) trades on the NASDAQ.
What sector is ALMS in?
Alumis Inc. (ALMS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alumis Inc.?
Martin Babler is the chief executive officer of Alumis Inc. (ALMS).
Where is Alumis Inc. headquartered?
Alumis Inc. is headquartered in United States.
Does ALMS pay a dividend?
Alumis Inc. (ALMS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALMS go public?
Alumis Inc. (ALMS) completed its initial public offering in 2024.